Agents inhibiting the synthesis, stability or activity of surface GRP78 can suppress the protein’s function in cancer proliferation4 and can be used in conjunction with other standard cytotoxic agents to enhance efficacy of anticancer treatment for glioma and other highly metastatic and resistant cancers exhibiting surface GRP78. The gene discussed is HSPA5; the disease is central nervous system cancer.